



For Immediate Release

**CyGenics secures exclusive licence on enhanced T cell production technologies from the Brigham and Women's Hospital
Exclusive worldwide licence from Harvard Medical School teaching affiliate**

6th OCTOBER 2004 – Stem cell biotechnology company, CyGenics Ltd (ASX: CYN) announced that, effective 21st September 2004, Cytomatrix LLC, the Boston-based research arm of the CyGenics group of companies, has secured an exclusive, worldwide licence agreement with the Brigham and Women's Hospital (BWH), a teaching hospital affiliated with Harvard Medical School and a Member of Partners HealthCare Organization. The licence agreement is for rights to a patent pending in the United States for a process that may significantly increase the number of T cells produced in the Company's T cell production system.

In 2000, Cytomatrix entered into a material transfer agreement with investigators at the BWH. Under this agreement, Cytomatrix provided its patented three-dimensional cell growth matrix and baseline T cell production technology to the Harvard hospital. Now, after four years of research, the BWH investigators have developed a process to enhance the T cell yield of the original growth system. The BWH filed a US patent on these enhancements in December 2003.

Cytomatrix has now secured the exclusive licence to use these enhancements for therapeutic purposes. Cytomatrix has obtained this licence for an in addition to reimbursement of patent costs undertaken by the BWH. As Cytomatrix develops the T cell production technology further, and achieves certain milestones, such as undertaking clinical trials or filing for US FDA approval, the company will pay BWH other fees and, ultimately, a royalty on commercial sales.



“This is an important advance in our T cell production capabilities,” said Dr. Mark Pykett, President, CyGenics. “We believe the improved process may accelerate the development of our T cell production for a range of uses. We are pleased that the use of Cytomatrix’ patented three-dimensional cell growth matrix by BWH investigators has led to this potentially powerful improvement, and we look to bring this T cell production capability through the next stages of development.”

About CyGenics

CyGenics is a biotechnology company focused on the development and commercialisation of stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates three divisions: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in the USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

For more information, please contact:

Ronald Hee	Rod Nockles
Corporate Communications & Marketing Manager	Director
CordLife Pte Ltd	Financial & Corporate Relations
600 North Bridge Road,	Level 20,
#12-09/10, Parkview Square,	114 William Street
Singapore 188778	Melbourne Victoria 3000
Singapore	Australia
Tel : +65 6238 0808	Tel: +61 3 9670 7996
Fax: +65 6295 1108	Fax: +61 3 9670 3883
Mobile: +65 9061 9098	Mobile: +61 (0) 419 691 323
Email: rhee@cordlife.com	E-mail: r.nockles@fcr.com.au